NEXGEL Appoints Joseph F. McGuire as Chief Financial Officer
MWN-AI** Summary
NEXGEL, Inc. (NASDAQ: NXGL), a prominent provider of medical and over-the-counter products featuring high-water-content hydrogels, has announced the appointment of Joseph F. McGuire as its new Chief Financial Officer, effective January 1, 2025. This strategic decision comes as the company seeks to enhance its operational and financial expertise amidst rapid growth. Adam E. Drapczuk III, who previously served as CFO, will transition to a consulting role with the company.
Adam Levy, CEO of NEXGEL, expressed enthusiasm for McGuire's addition to the team, highlighting his extensive experience—over 30 years in public company finance—which is seen as critical for the company during this pivotal time. McGuire's background includes significant roles in health care and financial services, and he played an essential part in a biotechnology firm's IPO that resulted in a listing on the NYSE in July 2022. His previous positions encompassed responsibilities in SEC reporting, investor relations, and corporate governance, bolstering his suitability for NEXGEL's finance leadership.
McGuire, who began consulting for NEXGEL in September 2024, emphasized his excitement about joining the firm, praising the existing leadership for their performance and ability to exceed market expectations.
NEXGEL, headquartered in Langhorne, Pennsylvania, has established itself through two decades of innovation in electron-beam, cross-linked hydrogels. The company’s product lineup includes well-known brands such as SilverSeal® and Turfguard®. McGuire's appointment signals NEXGEL's commitment to driving its growth trajectory and sustaining its competitive edge in the healthcare market.
MWN-AI** Analysis
As NEXGEL, Inc. (NASDAQ: NXGL) appoints Joseph F. McGuire as Chief Financial Officer, the company enters a pivotal phase poised for significant growth in the healthcare sector. His extensive experience in managing public company financials, particularly within biotech IPOs, could prove vital as NEXGEL navigates its trajectory in the competitive healthcare landscape.
Investors should view McGuire's appointment positively, as it signals a strategic move to reinforce the company's financial operations amid rising demand for innovative healthcare solutions. His background, spanning over three decades, encompasses pivotal roles in financial reporting, investor relations, and corporate governance—areas essential for enhancing shareholder confidence and sustaining market momentum.
Moreover, NEXGEL’s trajectory, particularly with its diversified portfolio of hydrogels, positions the company favorably within the healthcare and beauty markets. The consistent growth highlighted by CEO Adam Levy indicates a robust operational framework, which could lead to further market penetration and revenue expansion. The continuation of Adam Drapczuk as a consultant allows for a smoother transition and ensures that core business knowledge remains intact.
Investors should also monitor NEXGEL's strategic partnerships in contract manufacturing, which not only broaden product availability but also potentially stabilize revenue streams. These collaborations may enhance the company's market share and provide a buffer against sector volatility.
However, it is essential to remain vigilant regarding potential risks. As noted in the forward-looking statements, unforeseen challenges could affect projections. Investors are encouraged to review risk factors outlined in the Company’s 10-K filings to understand better the variables that could influence NEXGEL’s performance.
In summary, with a seasoned CFO at the helm, coupled with robust business fundamentals, NEXGEL presents a compelling investment opportunity in a high-growth sector. Potential investors should maintain a close watch on upcoming performance indicators and market developments.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
LANGHORNE, Pa., Jan. 02, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced the appointment of Joseph F. McGuire as Chief Financial Officer, effective January 1, 2025. Adam E. Drapczuk III, current Chief Financial Officer, will remain with the Company as a consultant.
Adam Levy, Chief Executive Officer, stated, “As our business continues to experience high growth, it is imperative we consistently acquire talented and experienced professionals to join our team particularly in operations and finance. Joe brings many decades of public company and financial experience that will be invaluable during this critical juncture in our company history.”
Mr. Levy continued, “I would like to thank Adam Drapczuk for his invaluable contributions to NEXGEL’s progress and success. We wish him good luck as he builds his own consulting business through Achieving Consulting Excellence, LLC, and are pleased that we can still rely on him moving forward.”
Mr. McGuire has over 30 years of financial and public company experience, having served as Chief Financial Officer for several privately held and publicly traded companies in the health care, financial services, investment, and manufacturing industries. He was a key member of the team that successfully guided a biotechnology company through its IPO, resulting in its listing on the NYSE in July 2022. In these roles, Mr. McGuire’s responsibilities included SEC financial reporting, investor relations, corporate governance, legal and audit liaison, and team building. He began his career with Price Waterhouse, where he was a certified public accountant, and later held management positions with Dean Witter Reynolds and Paine Webber, Inc. Mr. McGuire received a Bachelor of Science in accounting from the University of Notre Dame. Mr. McGuire has consulted with NEXGEL since September 2, 2024, and will serve on the executive management team to lead the Company’s finance functions.
Mr. McGuire, newly appointed Chief Financial Officer of NEXGEL, commented, “It is an exciting time to be part of NEXGEL. Adam Levy and his team have executed consistently and exceeded the markets expectations. I look forward to working with him, Adam Drapczuk and the rest of the team going forward.”
About NEXGEL, Inc.
NEXGEL is a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. NEXGEL brands include SilverSeal ® , Hexagels ® , Turfguard ® , Kenkoderm ® and Silly George ® . Additionally, NEXGEL has strategic contract manufacturing relationships with leading consumer healthcare companies.
Forward-Looking Statement
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs, such as “will,” “should,” “would,” “may,” and “could,” are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance, or achievements to be materially different from any anticipated results, performance, or achievements for many reasons. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company's forward-looking statements, please see the Company's Annual Report on Form 10-K for the year ended December 31, 2023, including but not limited to the discussion under “Risk Factors” therein, which the Company filed with the SEC and which may be viewed at http://www.sec.gov/ .
Investor Contacts:
Valter Pinto, Managing Director
KCSA Strategic Communications
212.896.1254
NEXGEL@KCSA.com
FAQ**
How does the appointment of Joseph F. McGuire as Chief Financial Officer impact NEXGEL Inc's strategy and growth trajectory, especially considering the importance of finance in the execution of its plans related to the NexGel Inc Warrant NXGLW?
What specific skills and experiences does Joseph F. McGuire bring that may enhance investor confidence in NEXGEL Inc, particularly regarding its financial reporting and handling of the NexGel Inc Warrant NXGLW?
With Adam E. Drapczuk III transitioning to a consultant role, what strategies will NEXGEL implement to ensure continuity in financial operations while optimizing the potential of the NexGel Inc Warrant NXGLW?
How does NEXGEL Inc plan to leverage McGuire's extensive experience to improve its investor relations as the company navigates through its current growth phase and the implications for the NexGel Inc Warrant NXGLW?
**MWN-AI FAQ is based on asking OpenAI questions about NexGel Inc (NASDAQ: NXGL).
NASDAQ: NXGL
NXGL Trading
14.42% G/L:
$0.595 Last:
377,697 Volume:
$0.53 Open:
